Schacter Named Clinical Trials Director at Yale
NEW HAVEN, Conn--Lee Philip Schacter, PhD, MD, has been named associate director for clinical trials for the Yale Cancer Center. In that role, he will oversee the clinical research projects on experimental cancer treatment taking place at the Center. Dr. Schacter comes to Yale from Bristol-Myers Squibb, where he was a director of the clinical cancer research program.
NEW HAVEN, Conn--Lee Philip Schacter, PhD, MD, has been namedassociate director for clinical trials for the Yale Cancer Center.In that role, he will oversee the clinical research projects onexperimental cancer treatment taking place at the Center. Dr.Schacter comes to Yale from Bristol-Myers Squibb, where he wasa director of the clinical cancer research program.
His top priority in his new position will be to further developmentof the Center's new clinical research program. "We have mostof the people in place," he said, referring to the Center'scorps of research scientists and physicians. "And we havepromising experimental treatment programs underway. That combinationmakes this a place people look to for progressive cancer therapy."
Dr. Schacter will also be instrumental in building a network forcommunity-based clinical research. The effort will involve extendingresearch projects to community hospitals throughout Connecticutas well as physicians' offices.
FDA Approves Encorafenib/Cetuximab Plus mFOLFOX6 for Advanced BRAF V600E+ CRC
December 20th 2024The FDA has granted accelerated approval to encorafenib in combination with cetuximab and mFOLFOX6 for patients with metastatic colorectal cancer with a BRAF V600E mutation, as detected by an FDA-approved test.
